New Management Team at Hemovent
With immediate effect, Dr. Jürgen O. Böhm will take on the role of corporate management at Hemovent GmbH. As the new Chief Executive Officer and Chief Medical Officer, he will support for the two previous Managing Directors and Founders Christof Lenz (CFO) and Dr. Oliver Marseille (CTO). The medical technology company with around 35 employees is thus gaining an experienced expert to expand its corporate development. Hemovent is prepared for the next growth phase thanks to this strategic addition to its management team.
“We are very glad that we were able to recruit Jürgen Böhm for Hemovent. His many years of experience using ECLS products and his expertise in corporate management and sales will help us to achieve our goals even more efficiently – of that I am sure,” said Christof Lenz, who is taking on a new role as CFO, effective immediately.
Dr. Böhm specialized in heart surgery and has over 12 years of clinical experience. He started his career in medical device industry as the Clinical Director at Maquet Cardiopulmonary AG. For the last 10 years he was a member of the Xenios AG Executive Board, where he was responsible for Clinical Affairs and Operations. He also drove and supported corporate development and realized innovative solutions for the treatment of heart and lung failure.
“I am very much looking forward to the new challenge of working at Hemovent. Christof Lenz and Oliver Marseille created an extremely innovative product, laying the foundation for entering the market and further sales growth. Now the successful market launch of the MOBYBOX™ System and consistent further development of our business are the highest priorities,” said Dr. Böhm.
Über die Hemovent GmbH
Hemovent is an emerging medical device company based in Aachen, Germany that has won multiple awards. Its MOBYBOX™ product is an extremely portable machine that easily fits in a backpack and is even easier to operate. With this highly innovative ECLS system, Hemovent wants to expand the application area of this life-saving technology for heart-lung support to a fully new dimension. Since 2021, Hemovent has been focusing on growth and aims to shape the future of the portable ECLS system market in intensive care medicine over the long term as a member of MicroPort®, a global medical devices company operating in multiple international markets.
Firmenkontakt und Herausgeber der Meldung:
Hemovent GmbH
Pascalstr. 59
52076 Aachen
Telefon: +49 (241) 9901330
http://hemovent.com
Ansprechpartner:
Sandra Bastian
Manager Marketing & Communication
Telefon: +49 (241) 990133-27
E-Mail: sbastian@hemovent.com
Manager Marketing & Communication
Telefon: +49 (241) 990133-27
E-Mail: sbastian@hemovent.com
Weiterführende Links
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.
